Hematologic Malignancy

Plasma Cell Neoplasm

HematologicNon-malignant831 active trials25 approved drugs26 evidence items

NCIt: C4665
MeSH: D054219

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Literature

Linked publications (117)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 51–75 of 117 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma.
Noé Perron, Kane Foster, Tarek H Mouhieddine et al. · Leukemia · Sep 3, 2026 · PMID 42693161 · candidate dictionary pubmed
A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma.
Ricardo Ahrens, Kyra Ahrens, Maximilian Al-Bazaz et al. · Blood Cancer J · Sep 3, 2026 · PMID 42693082 · candidate dictionary pubmed
Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents.
Hitomi Nakayama, Tomonori Nakazato, Atsushi Takahata et al. · Br J Haematol · Sep 3, 2026 · PMID 42692463 · candidate dictionary pubmed
Machine Learning and Molecular Modeling Reveal HDAC6 as a Key Target of Tanshinone IIA in Multiple Myeloma.
Jian Gao, Jiawen Chu, Pengpeng Li · J Phys Chem B · Sep 3, 2026 · PMID 42691419 · candidate dictionary pubmed
Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.
Marie Christine Wesener, Uta Margareta Demel, Thomas Pabst et al. · Haematologica · Sep 3, 2026 · PMID 42687830 · candidate dictionary pubmed
Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma.
Sagar Lonial, Paul G Richardson, Geraldine Ferron-Brady et al. · Haematologica · Sep 3, 2026 · PMID 42687822 · candidate dictionary

pubmed

Independent prognostic value of semaphorin-4D, interleukin-1β and complement activation in newly diagnosed multiple myeloma patients.

Ioannis Ntanasis-Stathopoulos, Panagiota-Efstathia Nikolaou, Charalampos Filippatos et al. · Haematologica · Sep 3, 2026 · PMID 42687818 · candidate dictionary pubmed

Fixed-duration lenalidomide maintenance: considering environmental value in multiple myeloma.

Max Piffoux, Sebastien Taillemite · Haematologica · Sep 3, 2026 · PMID 42687812 · candidate dictionary pubmed

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience.

Cirino Botta, Andrea Rizzuto, Maria Speciale et al. · Haematologica · Sep 3, 2026 · PMID 42687806 · candidate dictionary pubmed

Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma.

Rahul Banerjee · Blood Cancer Discov · Sep 3, 2026 · PMID 42593166 · candidate dictionary pubmed

Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry.

Kylee H Maclachlan, Marios Papadimitriou, Patrick Blaney et al. · Blood Cancer Discov · Sep 3, 2026 · PMID 42284538 · candidate dictionary pubmed

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Maximilian Merz, Tomas Jelinek, Thomas Pabst et al. · Blood Cancer Discov · Sep 3, 2026 · PMID 42284467 · candidate dictionary pubmed

A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study.

Song Jin, Zhaohui Liao, Shuang Yan et al. · Blood · Sep 3, 2026 · PMID 42275247 · candidate dictionary pubmed

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

Susan Bal, Myo Htut, Omar Nadeem et al. · Blood · Sep 3, 2026 · PMID 42233419 · candidate dictionary pubmed

Dynamic multimodal survival prediction in multiple myeloma integrating gene expression, longitudinal laboratory measurements, and treatment history.

Shangru Jia, Artem Lysenko, Keith A Boroevich et al. · Brief Bioinform · Sep 1, 2026 · PMID 42704271 · candidate dictionary pubmed

Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting.

Oliver Henriques Peck, Aimee McCoubrey, John A Snowden et al. · Open Heart · Sep 1, 2026 · PMID 42680232 · candidate dictionary pubmed

GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.

Darren Pan, Anupama Kumar, Jodi J Lipof et al. · Cancer · Sep 1, 2026 · PMID 42675812 · candidate dictionary pubmed

Racial differences in multiple myeloma survival: Associations with stem cell transplantation, insurance, and Medicaid expansion.

F Lennie Wong, Scott R Goldsmith, Kimlin Ashing et al. · Cancer · Sep 1, 2026 · PMID 42663244 · candidate dictionary pubmed

Methylation variability and LINE-1 transcriptional activation in multiple myeloma.

Qianhui Wan, Amy Leung, Mahek Vinod Bhandari et al. · Genome Res · Sep 1, 2026 · PMID 42469014 · candidate dictionary pubmed

Establishment of a Multimodal Prognostic Prediction Model for Multiple Myeloma Patients Based on Radiomics and Clinical Features: A Retrospective Cohort Study.

Shiqi Sun, Zejing Huang, Yunlong Tang et al. · Turk J Haematol · Sep 1, 2026 · PMID 42460671 · candidate dictionary pubmed

A U-Shaped Association: The First-Year eGFR Slope and Mortality Risk in Multiple Myeloma.

Lian Li, Xiang Liu, Mingjing Guan et al. · Cancer Med · Sep 1, 2026 · PMID 42702740 · candidate dictionary pubmed

Construction and Validation of a Progression-Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification.

Yuexuan Rao, Shiyou Li, Aoyang Yu et al. · Cancer Med · Sep 1, 2026 · PMID 42701330 · candidate dictionary pubmed

Sparse integrative dictionary learning resolves conserved drug-response states in multiple myeloma (MM).

Mingke Wu, Jin Lu, Qing Ge · Cancer Genet · Sep 1, 2026 · PMID 42600555 · candidate dictionary pubmed

Clonal Hematopoiesis in Newly Diagnosed Multiple Myeloma: Associations With Neutropenia, Supportive Care Burden, and Survival.

Ahmet Yigitbasi, Fulya Oz Puyan, Hakki Onur Kirkizlar et al. · Clin Lymphoma Myeloma Leuk · Sep 1, 2026 · PMID 42567754 · candidate dictionary pubmed

Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis.

Yubiao Pan, Yue Wang, Yaqin Xiong et al. · Hematol Oncol · Sep 1, 2026 · PMID 42549699 · candidate dictionary pubmed